Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-29

Serine proteinase inhibitors for therapy of inflammatory skin diseases

Objective

Currently, no specific and causative therapy for the treatment of inflammatory skin diseases, e.g. atopic dermatitis and psoriasis, is available. To create new treatment options for these diseases, the applicants plan a strategic partnership by the mutual exchange of knowledge. Both the industrial partner, IPF PharmaCeuticals (Hannover, Germany), and the academic partner, Centro de Investigaciones Biologicas (Madrid, Spain), will contribute to the know-how transfer in the field of applied protein research for the examination of newly discovered serine proteinases and their inhibitors. A multi-domain serine proteinase inhibitor (LEKTI) was identified and was shown to play a significant role in the development of skin diseases.

Based on these findings, the proposed research aims to examine the (patho-)physiological role of relevant serine proteinases and their pertinent inhibitors for the discovery of new drugs against skin diseases. The cooperation between the German company and the institution from the Spanish Council of Scientific Research (CSIC) will result in a long-lasting strategic partnership taking advantage of complementary know-how of each organization and of the different scientific and economic networks in these two countries of the EC.The applicants have a long-standing experience in the organization of scientific research collaborations, workshops, execution of scientific grants, publications, patent issues and in the exploition of intellectual property rights.

This research co-operation plans (i) to identify and produce serine proteinases and their inhibitors related to atopic dermatitis and psoriasis, (ii) to elucidate their three-dimensional structure, (iii) on the basis of this knowledge to design optimized inhibitors, and (iv) to test the pharmacological potential of the inhibitors in animal models for skin diseases.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2002-MOBILITY-3
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

TOK - Marie Curie actions-Transfer of Knowledge

Coordinator

IPF PHARMACEUTICALS
EU contribution
No data
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (1)

My booklet 0 0